On Monday, the Fourth Circuit Court of Appeals in the United States issued an opinion supporting the decision made by the Food and Drug Administration (FDA) to deny Avail Vapor LLC's application to sell its flavored electronic cigarettes and to reject Avail's review request.
According to this opinion, the Tobacco Control Act (TCA) requires manufacturers of new tobacco products to obtain FDA authorization through a pre-market tobacco product application (PMTA) before selling these products. The TCA further requires the FDA to determine whether the marketing of new tobacco products is "appropriate for protecting public health" in order to authorize PMTA.
Avail Vapor is a company that sells electronic cigarette products regulated by the FDA through TCA. This statement indicates that in the constantly developing regulatory framework for electronic cigarettes, Avail submitted a PMTA to the FDA for approval on September 8, 2020.
The court stated that in 2019, the FDA issued new guidelines on the premarket tobacco product application (PMTA) for e-cigarettes to address the "youth e-cigarette epidemic." Specifically, the FDA stated that enforcement decisions would be made based on specific circumstances and that they would continue to evaluate new information to address the growing problem of underage use of flavored e-cigarettes. Additionally, manufacturers of existing e-cigarette tobacco products must submit a PMTA.
According to the opinion, Avail will submit its PMTA for FDA approval before the specified deadline. The court noted that Avail's PMTA focuses on various fruit and dessert-flavored electronic cigarettes. Additionally, Avail has provided a marketing plan that outlines measures to prevent underage use, including giving flavors unusual names, age-restricted physical stores, and sales point systems.
However, on September 15, 2021, the FDA rejected Avail's PMTA and issued a marketing refusal order for its products. In the refusal order, the FDA stated that Avail's products pose a serious risk to adolescents and do not have sufficient offsetting benefits for adults.
Subsequently, Avail filed an administrative appeal against the order, but on February 23, 2022, the FDA upheld its decision and reiterated its concerns for minors' safety. Avail promptly requested that the Fourth Circuit Court review the FDA's refusal order, arguing that it imposed arbitrary standards on the types of information manufacturers must provide in PMTAs and that the FDA's imposition of these standards exceeded its statutory authority.
In a unanimous decision, the court found that the Tobacco Control Act (TCA) grants the FDA broad statutory authority to determine whether the marketing of a new tobacco product is "appropriate for the protection of public health" based on all evidence received. Additionally, the court stated that Avail's arguments and restrictions "completely contradict" the requirements of the FDA under the TCA. Therefore, the court found that the FDA's standards for evaluating information during its PMTA review were fully within its statutory authority.
Furthermore, the court found that the FDA's denial of Avail's PMTA was "hardly arbitrary," and that it appropriately evaluated the evolving science and ever-changing market when assessing the significant risks of teenage addiction to flavored e-cigarettes. Therefore, the court confirmed the FDA's rejection order and denied Avail's request for a review.
Avail is being represented by Thompson Hine LLP.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
